Emin Baris Akin
Research Subjects
Emin Baris Akin has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Ayşe Sinangil
DEMİROĞLU BİLİM ÜNİVERSİTESİ, TIP FAKÜLTESİ
3 shared publications - Zuhal Atan Ucar
Liv Hospital Vadistanbul
3 shared publications - Ahmet Burak Dirim
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
2 shared publications - Alaattin Yildiz
Division of Nephrology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
2 shared publications David Cucchiari
European Kidney Transplant Association, Section of European Society of Transplantation, Netherlands
2 shared publications- Ergün Parmaksız
Department of Nephrology Kartal Dr. Lütfi Kırdar Training and Research Hospital, University of Health Sciences Istanbul Turkey
2 shared publications
Latest Publications
- 13 July 2026
- Published by Doc Design and Informatics Co. Ltd. in Turkish Journal of Immunology
HLA Allele Distribution in Patients with End-Stage Renal Disease: A Cross-Sectional Study
Objective: Our study was conducted to analyze the association between HLA polymorphism and end stage renal disease (ESRD) in patients and to determine the underlying mechanisms of the onset and progression of renal failure. Materials and Methods: In our study we included 120 patients on the kidney transplant waiting list and 100 unrelated donors who underwent HLA typing using the polymerase chain reaction-sequence specific primer (SSP) method at the Tissue Typing Laboratory of Demiroğlu Bilim University Gayrettepe Florence Nightingale Hospital in between 2021-2023. The frequencies of HLA-A,-B,-DRB1 alleles were compared between ESRD patients and the control group, and the relationship between ESRD risk factors, HLA allele frequency (AF), haplotype frequency (HF) was investigated. Results: Similar alleles were observed at high frequencies in both the ESRD patient and control groups, with these alleles which are HLA-A*02 (0.239/0.245), HLA-B*35 (0.225/0.183), and HLA-DRB1*11 (0.230/0.216). The most common haplotypes in patients were A*24~B*35~DR*11 (0.0495), A*02~B*51~DR*11 (0.0485), A*03~B*44~DR*04 (0.0270), A*11~B*35~DR*01 (0.0225), A*02~B*35~DR*04 (0.0225), while in controls they were A*24~B*35~DR*11 (0.0231), A*23~B*49~DR*11 (0.0192), A*02~B*51~DR*13 (0.0179), A*03~B*18~DR*11 (0.0149), A*02~B*18~DR*04 (0.0142) in the controls. For the HLA-B locus, the risk factors were B*50 (p:0.017), B*51 (p <0.0001), B*52 (p:0.023), B*55 (p:0.0017), B*57 (p:0.0017) were identified as risk factors, while B*14 (p:0.016), B*15 (p:0.002) were identified as protective factors. Furthermore, in patients with a primary diagnosis of diabetic nephropathy, A*11 (25.0%), B*51 (31.3%), DRB1*11 (25%) were found at high frequencies. A*02 (27.3%), B*35 (36.4%), DRB1*04 (22.7%) were found at high frequencies in patients with a primary diagnosis of polycystic kidney disease. Conclusion: This study has revealed the relationship between HLA polymorphism and susceptibility to ESRD in the patient population. In patients awaiting kidney transplantation, five susceptible alleles and four susceptible haplotypes were identified. These HLA alleles and haplotypes might serve as genetic markers for susceptibility to ESRD in our population. Keywords: End stage renal disease, human leukocyte antigen, haplotype, alleles frequency
- 13 July 2026
- Published by Doc Design and Informatics Co. Ltd. in Turkish Journal of Immunology
HLA Allele Distribution in Patients with End-Stage Renal Disease: A Cross-Sectional Study
Objective: Our study was conducted to analyze the association between HLA polymorphism and end stage renal disease (ESRD) in patients and to determine the underlying mechanisms of the onset and progression of renal failure. Materials and Methods: In our study we included 120 patients on the kidney transplant waiting list and 100 unrelated donors who underwent HLA typing using the polymerase chain reaction-sequence specific primer (SSP) method at the Tissue Typing Laboratory of Demiroğlu Bilim University Gayrettepe Florence Nightingale Hospital in between 2021-2023. The frequencies of HLA-A,-B,-DRB1 alleles were compared between ESRD patients and the control group, and the relationship between ESRD risk factors, HLA allele frequency (AF), haplotype frequency (HF) was investigated. Results: Similar alleles were observed at high frequencies in both the ESRD patient and control groups, with these alleles which are HLA-A*02 (0.239/0.245), HLA-B*35 (0.225/0.183), and HLA-DRB1*11 (0.230/0.216). The most common haplotypes in patients were A*24~B*35~DR*11 (0.0495), A*02~B*51~DR*11 (0.0485), A*03~B*44~DR*04 (0.0270), A*11~B*35~DR*01 (0.0225), A*02~B*35~DR*04 (0.0225), while in controls they were A*24~B*35~DR*11 (0.0231), A*23~B*49~DR*11 (0.0192), A*02~B*51~DR*13 (0.0179), A*03~B*18~DR*11 (0.0149), A*02~B*18~DR*04 (0.0142) in the controls. For the HLA-B locus, the risk factors were B*50 (p:0.017), B*51 (p <0.0001), B*52 (p:0.023), B*55 (p:0.0017), B*57 (p:0.0017) were identified as risk factors, while B*14 (p:0.016), B*15 (p:0.002) were identified as protective factors. Furthermore, in patients with a primary diagnosis of diabetic nephropathy, A*11 (25.0%), B*51 (31.3%), DRB1*11 (25%) were found at high frequencies. A*02 (27.3%), B*35 (36.4%), DRB1*04 (22.7%) were found at high frequencies in patients with a primary diagnosis of polycystic kidney disease. Conclusion: This study has revealed the relationship between HLA polymorphism and susceptibility to ESRD in the patient population. In patients awaiting kidney transplantation, five susceptible alleles and four susceptible haplotypes were identified. These HLA alleles and haplotypes might serve as genetic markers for susceptibility to ESRD in our population. Keywords: End stage renal disease, human leukocyte antigen, haplotype, alleles frequency
- Open Access
- 9 January 2026
- Published by Frontiers Media SA in Transplant International
- Vol. 38, 16128
Corrigendum: Vascular Access Management After Kidney Transplantation Position Paper on Behalf of the Vascular Access Society and the European Kidney Transplant Association
There was a mistake in Figure 2
- 9 January 2026
- Published by Frontiers Media SA in Transplant International
- Vol. 38, 16128
Open AccessCorrigendum: Vascular Access Management After Kidney Transplantation Position Paper on Behalf of the Vascular Access Society and the European Kidney Transplant Association
There was a mistake in Figure 2
- Open Access
- 13 November 2025
- Published by Frontiers Media SA in Transplant International
- Vol. 38, 14712
Vascular Access Management After Kidney Transplantation Position Paper on Behalf of the Vascular Access Society and the European Kidney Transplant Association
There is no consensus on whether to ligate or preserve uncomplicated vascular access (VA) after kidney transplantation (KT), as International Guidelines do not address this issue. Enhanced survival rates of kidney grafts may elevate the risk of cardiac morbidity and mortality due to prolonged exposure to the hemodynamic effects of arterio-venous fistulas (AVF). Although VA ligation reduces left ventricle (LV) mass, its impact on cardiovascular (CV) morbidity or mortality is unclear. High-flow VAs can complicate KT patients, and immunosuppressive medication may increase these complications. Despite preserving VA for future hemodialysis (HD) use, central catheters are used in nearly two-thirds of patients. Detecting transplant patients who can undergo AVF ligation and reconstruction when returning to HD allows for flexible decision-making with a multidisciplinary approach, personally tailored to patients at their discretion. Therefore, an algorithm involving Doppler ultrasound and cardiac evaluation is advisable.
- 13 November 2025
- Published by Frontiers Media SA in Transplant International
- Vol. 38, 14712
Open AccessVascular Access Management After Kidney Transplantation Position Paper on Behalf of the Vascular Access Society and the European Kidney Transplant Association
There is no consensus on whether to ligate or preserve uncomplicated vascular access (VA) after kidney transplantation (KT), as International Guidelines do not address this issue. Enhanced survival rates of kidney grafts may elevate the risk of cardiac morbidity and mortality due to prolonged exposure to the hemodynamic effects of arterio-venous fistulas (AVF). Although VA ligation reduces left ventricle (LV) mass, its impact on cardiovascular (CV) morbidity or mortality is unclear. High-flow VAs can complicate KT patients, and immunosuppressive medication may increase these complications. Despite preserving VA for future hemodialysis (HD) use, central catheters are used in nearly two-thirds of patients. Detecting transplant patients who can undergo AVF ligation and reconstruction when returning to HD allows for flexible decision-making with a multidisciplinary approach, personally tailored to patients at their discretion. Therefore, an algorithm involving Doppler ultrasound and cardiac evaluation is advisable.
- Open Access
- 20 July 2023
- Published by Gaziantep Islam Science and Technology University in Experimental and Applied Medical Science
- Vol. 4 (1) , 477-486
Clinicopathological Results of Percutaneous Transplant Kidney Biopsies: Single Center Nine Years' Experience
Background: Based on clinical criteria alone, the cause of graft dysfunction cannot be accurately predicted in 40-70% of cases. Therefore, renal allograft biopsy is still the gold standard for accurate diagnosis. We performed this study to evaluate the causes of renal graft dysfunction detected in renal allograft biopsies in our center. Methods: The results of 90 patients who underwent renal allograft biopsy between May 2013 and June 2022 from kidney transplant patients were evaluated retrospectively. Results: It was determined that 92 biopsies were performed from 90 patients and all were ‘cause’’ biopsies. The mean age was 40.03±14.29 years. 82 of the kidney transplants were from living donors. 21 patients had preemptive transplantation. The type of renal replacement therapy before transplantation was hemodialysis in 52 patients, PD in 3 patients, PD and HD in 3 patients. The reason for biopsy was high creatinine in 67 patients, proteinuria in 23 patients, and BKV viremia in 2 patients. The mean discharge creatinine value was 1.64±1.11mg/dl, and the mean creatinine before biopsy was 3.06±2.07mg/dl. Although there was kidney tissue in one of the allograft biopsies, there was no glomeruli. The mean number of cores taken was 2.94±0.61, and the number of glomeruli was 21.33±11.64. In one of the 92 biopsies performed, bleeding requiring transfusion developed. No other biopsy-related complications were observed. Graft loss was observed in 46 of 90 patients during the follow-up period. Conclusions: Evaluation of serum creatinine and urinalysis may be useful in predicting histological graft diagnosis, but an allograft biopsy is necessary for definitive diagnosis.
- 20 July 2023
- Published by Gaziantep Islam Science and Technology University in Experimental and Applied Medical Science
- Vol. 4 (1) , 477-486
Open AccessClinicopathological Results of Percutaneous Transplant Kidney Biopsies: Single Center Nine Years' Experience
Background: Based on clinical criteria alone, the cause of graft dysfunction cannot be accurately predicted in 40-70% of cases. Therefore, renal allograft biopsy is still the gold standard for accurate diagnosis. We performed this study to evaluate the causes of renal graft dysfunction detected in renal allograft biopsies in our center. Methods: The results of 90 patients who underwent renal allograft biopsy between May 2013 and June 2022 from kidney transplant patients were evaluated retrospectively. Results: It was determined that 92 biopsies were performed from 90 patients and all were ‘cause’’ biopsies. The mean age was 40.03±14.29 years. 82 of the kidney transplants were from living donors. 21 patients had preemptive transplantation. The type of renal replacement therapy before transplantation was hemodialysis in 52 patients, PD in 3 patients, PD and HD in 3 patients. The reason for biopsy was high creatinine in 67 patients, proteinuria in 23 patients, and BKV viremia in 2 patients. The mean discharge creatinine value was 1.64±1.11mg/dl, and the mean creatinine before biopsy was 3.06±2.07mg/dl. Although there was kidney tissue in one of the allograft biopsies, there was no glomeruli. The mean number of cores taken was 2.94±0.61, and the number of glomeruli was 21.33±11.64. In one of the 92 biopsies performed, bleeding requiring transfusion developed. No other biopsy-related complications were observed. Graft loss was observed in 46 of 90 patients during the follow-up period. Conclusions: Evaluation of serum creatinine and urinalysis may be useful in predicting histological graft diagnosis, but an allograft biopsy is necessary for definitive diagnosis.
- Open Access
- 5 April 2023
- Published by Afyon Kocatepe University in Kocatepe Tıp Dergisi
- Vol. 24 (2) , 234-240
PREOPERATIVE EVALUATION OF LIVING DONOR KIDNEY VARIATIONS WITH MULTIDETECTOR COMPUTED TOMOGRAPHY AND COMPARISON OF RESULTS WITH INTRAOPERATIVE FINDINGS
AMAÇ: Bu çalışmayla, çok kesitli bilgisayarlı tomografi (ÇKBT) kullanarak canlı böbrek donörlerinde renal vasküler ve toplayıcı sistem varyasyonlarını değerlendirmek ve verileri retroperitonoskopik donör nefrektomisinde saptanan bulgular ile karşılaştırmak amaçlanmıştır. GEREÇ VE YÖNTEM: Çalışmaya, Ocak 2015 ile Ekim 2021 arasında merkezimizde retroperitonoskopik donör nefrektomisi olan ve operasyon öncesi uygun protokol ile gerçekleştirilmiş ÇKBT görüntülemesi mevcut olan 652 donör dahil edildi. Böbreklerdeki arteryel, venöz ve toplayıcı sistem varyasyonları ÇKBT incelemesiyle değerlendirilip not edilerek sonuçlar operasyon bulguları ile karşılaştırıldı. BULGULAR: Donörlerin %72,7’sine (474 kişi) sol nefrektomi, kalan 178 donöre (%27,3) ise sağ nefrektomi yapıldı. Nakledilen 652 böbreğin 99’unda (%15,1) çift arter, 11’inde (%1,6) üç arter ve 1’inde (%<1) dört arter mevcut iken; 14 (%2,1) böbrekte erken arteryel segmentasyon saptandı. Laparoskopik bulgulara göre 26 (%4) donör böbrekte çift renal ven, 3 (%0,4) böbrekte üç adet renal ven mevcut iken; 8 donörde yapısal venöz varyasyon ve 6 donörde toplayıcı sistem varyasyonu görüldü. Aksesuar arter varlığını saptamada, ÇKBT’nin duyarlılık, özgüllük, pozitif-negatif öngörü değeri ve doğruluk oranları sırasıyla %97,3; %98,5; %93,1; %99,4 ve %98,3 olarak bulundu. Arter sayılarını saptamadaki doğruluğu ise %98 olarak hesaplandı. Venlerdeki sayısal varyasyonu saptamada ÇKBT’nin duyarlılık, özgüllük, pozitif-negatif öngörü değeri ve doğruluk oranları sırasıyla %100; %99,8; %96,5; %100 ve %99,8 olarak bulundu. Ven sayılarını saptamadaki doğruluğu ise %99,8 olarak hesaplandı. Arteryel erken segmentasyon, geç venöz konfluens ve toplayıcı sistem varyasyonlarını tespit etmede ise %100 başarı sağlandı. SONUÇ: Doğru teknik ile gerçekleştirilen ÇKBT, canlı donör böbrek nakli için donör adaylarında renal vasküler ve toplayıcı sistem varyasyonlarının değerlendirilmesi için oldukça doğru bir yöntemdir.
- 5 April 2023
- Published by Afyon Kocatepe University in Kocatepe Tıp Dergisi
- Vol. 24 (2) , 234-240
Open AccessPREOPERATIVE EVALUATION OF LIVING DONOR KIDNEY VARIATIONS WITH MULTIDETECTOR COMPUTED TOMOGRAPHY AND COMPARISON OF RESULTS WITH INTRAOPERATIVE FINDINGS
AMAÇ: Bu çalışmayla, çok kesitli bilgisayarlı tomografi (ÇKBT) kullanarak canlı böbrek donörlerinde renal vasküler ve toplayıcı sistem varyasyonlarını değerlendirmek ve verileri retroperitonoskopik donör nefrektomisinde saptanan bulgular ile karşılaştırmak amaçlanmıştır. GEREÇ VE YÖNTEM: Çalışmaya, Ocak 2015 ile Ekim 2021 arasında merkezimizde retroperitonoskopik donör nefrektomisi olan ve operasyon öncesi uygun protokol ile gerçekleştirilmiş ÇKBT görüntülemesi mevcut olan 652 donör dahil edildi. Böbreklerdeki arteryel, venöz ve toplayıcı sistem varyasyonları ÇKBT incelemesiyle değerlendirilip not edilerek sonuçlar operasyon bulguları ile karşılaştırıldı. BULGULAR: Donörlerin %72,7’sine (474 kişi) sol nefrektomi, kalan 178 donöre (%27,3) ise sağ nefrektomi yapıldı. Nakledilen 652 böbreğin 99’unda (%15,1) çift arter, 11’inde (%1,6) üç arter ve 1’inde (%<1) dört arter mevcut iken; 14 (%2,1) böbrekte erken arteryel segmentasyon saptandı. Laparoskopik bulgulara göre 26 (%4) donör böbrekte çift renal ven, 3 (%0,4) böbrekte üç adet renal ven mevcut iken; 8 donörde yapısal venöz varyasyon ve 6 donörde toplayıcı sistem varyasyonu görüldü. Aksesuar arter varlığını saptamada, ÇKBT’nin duyarlılık, özgüllük, pozitif-negatif öngörü değeri ve doğruluk oranları sırasıyla %97,3; %98,5; %93,1; %99,4 ve %98,3 olarak bulundu. Arter sayılarını saptamadaki doğruluğu ise %98 olarak hesaplandı. Venlerdeki sayısal varyasyonu saptamada ÇKBT’nin duyarlılık, özgüllük, pozitif-negatif öngörü değeri ve doğruluk oranları sırasıyla %100; %99,8; %96,5; %100 ve %99,8 olarak bulundu. Ven sayılarını saptamadaki doğruluğu ise %99,8 olarak hesaplandı. Arteryel erken segmentasyon, geç venöz konfluens ve toplayıcı sistem varyasyonlarını tespit etmede ise %100 başarı sağlandı. SONUÇ: Doğru teknik ile gerçekleştirilen ÇKBT, canlı donör böbrek nakli için donör adaylarında renal vasküler ve toplayıcı sistem varyasyonlarının değerlendirilmesi için oldukça doğru bir yöntemdir.
- Open Access
- 12 May 2022
- Published by Springer Nature in BMC Nephrology
- Vol. 23 (1) , 1-13
COVID-19 in Kidney Transplant Recipients: A Multicenter Experience from the First Two Waves of Pandemic
Background: Kidney transplant recipients have an increased risk of complications from COVID-19. However, data on the risk of allograft damage or death in kidney transplant recipients recovering from COVID-19 is limited. In addition, the first and second waves of the pandemic occurred at different times all over the world. In Turkey, the Health Minister confirmed the first case in March 2020; after that, the first wave occurred between March and August 2020; afterward, the second wave began in September 2020. This study aims to demonstrate the clinical presentations of kidney transplant recipients in the first two waves of the pandemic in Turkey and explore the impact of COVID-19 on clinical outcomes after the initial episode. Methods: Patients with COVID-19 from seven centers were included in this retrospective cohort study. Initially, four hundred and eighty-eight kidney transplant recipients diagnosed with COVID-19 between 1 March 2020 to 28 February 2021 were enrolled. The endpoints were the occurrence of all-cause mortality, acute kidney injury, cytokine storm, and acute respiratory distress syndrome. In addition, longer-term outcomes such as mortality, need for dialysis, and allograft function of the surviving patients was analyzed. Results: Four hundred seventy-five patients were followed up for a median of 132 days after COVID-19. Forty-seven patients (9.9%) died after a median length of hospitalization of 15 days. Although the mortality rate (10.1% vs. 9.8%) and intensive care unit admission (14.5% vs. 14.5%) were similar in the first two waves, hospitalization (68.8% vs. 29.7%; p < 0.001), acute kidney injury (44.2% vs. 31.8%; p = 0.009), acute respiratory distress syndrome (18.8% vs. 16%; p = 0.456), and cytokine storm rate (15.9% vs. 10.1%; p = 0.072) were higher in first wave compared to the second wave. These 47 patients died within the first month of COVID-19. Six (1.4%) of the surviving patients lost allografts during treatment. There was no difference in the median serum creatinine clearance of the surviving patients at baseline (52 mL/min [IQR, 47–66]), first- (56 mL/min [IQR, 51–68]), third- (51 mL/min [IQR,48–67]) and sixth-months (52 mL/min [IQR, 48–81]). Development of cytokine storm and posttransplant diabetes mellitus were independent predictors for mortality. Conclusions: Mortality remains a problem in COVID-19. All the deaths occur in the first month of COVID-19. Also, acute kidney injury is common in hospitalized patients, and some of the patients suffer from graft loss after the initial episode.
- 12 May 2022
- Published by Springer Nature in BMC Nephrology
- Vol. 23 (1) , 1-13
Open AccessCOVID-19 in Kidney Transplant Recipients: A Multicenter Experience from the First Two Waves of Pandemic
Background: Kidney transplant recipients have an increased risk of complications from COVID-19. However, data on the risk of allograft damage or death in kidney transplant recipients recovering from COVID-19 is limited. In addition, the first and second waves of the pandemic occurred at different times all over the world. In Turkey, the Health Minister confirmed the first case in March 2020; after that, the first wave occurred between March and August 2020; afterward, the second wave began in September 2020. This study aims to demonstrate the clinical presentations of kidney transplant recipients in the first two waves of the pandemic in Turkey and explore the impact of COVID-19 on clinical outcomes after the initial episode. Methods: Patients with COVID-19 from seven centers were included in this retrospective cohort study. Initially, four hundred and eighty-eight kidney transplant recipients diagnosed with COVID-19 between 1 March 2020 to 28 February 2021 were enrolled. The endpoints were the occurrence of all-cause mortality, acute kidney injury, cytokine storm, and acute respiratory distress syndrome. In addition, longer-term outcomes such as mortality, need for dialysis, and allograft function of the surviving patients was analyzed. Results: Four hundred seventy-five patients were followed up for a median of 132 days after COVID-19. Forty-seven patients (9.9%) died after a median length of hospitalization of 15 days. Although the mortality rate (10.1% vs. 9.8%) and intensive care unit admission (14.5% vs. 14.5%) were similar in the first two waves, hospitalization (68.8% vs. 29.7%; p < 0.001), acute kidney injury (44.2% vs. 31.8%; p = 0.009), acute respiratory distress syndrome (18.8% vs. 16%; p = 0.456), and cytokine storm rate (15.9% vs. 10.1%; p = 0.072) were higher in first wave compared to the second wave. These 47 patients died within the first month of COVID-19. Six (1.4%) of the surviving patients lost allografts during treatment. There was no difference in the median serum creatinine clearance of the surviving patients at baseline (52 mL/min [IQR, 47–66]), first- (56 mL/min [IQR, 51–68]), third- (51 mL/min [IQR,48–67]) and sixth-months (52 mL/min [IQR, 48–81]). Development of cytokine storm and posttransplant diabetes mellitus were independent predictors for mortality. Conclusions: Mortality remains a problem in COVID-19. All the deaths occur in the first month of COVID-19. Also, acute kidney injury is common in hospitalized patients, and some of the patients suffer from graft loss after the initial episode.
- 25 January 2021
- Published by Wiley in Journal of Renal Care
- Vol. 48 (1) , 41-48
Relationship between arteriovenous fistula cannulation practices and dialysis adequacy: A prospective, multicenter study
Background: Successful arteriovenous fistula cannulation ensures maximum patient benefit in the haemodialysis procedure.Objective: The aim of this study was to determine the effect of various cannulation methods used for arteriovenous fistulas on dialysis adequacy.Design: It is a descriptive, cross‐sectional and multicenter study.Participants: A total of 164 dialysis patients from four dialysis centers were included.Measurements: Data were collected by determining patients' characteristics and the arteriovenous fistula cannulation method used, in addition to recording the Kt/V and urea reduction ratio values to evaluate dialysis adequacy. The mean Kt/V and urea reduction ratio values over 3 months after dialysis initiation were used. This trial is registered with ClinicalTrials.gov, NCT04270292.Results: Cannulation with the puncture method was used in 53% of the patients; the fistula needles were inserted in the antegrade direction in 43.9% of the patients; the arterial needle was rotated after fistula needle placement in 63.4% of the patients; and the arterial and venous needles were on the same vascular line in 15.2% of the patients. Placement of the fistula needle in the antegrade direction increased the Kt/V value 0.164 times (95% confidence interval: 0.002–0.212, p = .047).Conclusion: Antegrade placement could be a factor influencing dialysis adequacy. We suggest antegrade interventions to the fistula to maximize the patient benefit from the haemodialysis treatment.
- 25 January 2021
- Published by Wiley in Journal of Renal Care
- Vol. 48 (1) , 41-48
Relationship between arteriovenous fistula cannulation practices and dialysis adequacy: A prospective, multicenter study
Background: Successful arteriovenous fistula cannulation ensures maximum patient benefit in the haemodialysis procedure.Objective: The aim of this study was to determine the effect of various cannulation methods used for arteriovenous fistulas on dialysis adequacy.Design: It is a descriptive, cross‐sectional and multicenter study.Participants: A total of 164 dialysis patients from four dialysis centers were included.Measurements: Data were collected by determining patients' characteristics and the arteriovenous fistula cannulation method used, in addition to recording the Kt/V and urea reduction ratio values to evaluate dialysis adequacy. The mean Kt/V and urea reduction ratio values over 3 months after dialysis initiation were used. This trial is registered with ClinicalTrials.gov, NCT04270292.Results: Cannulation with the puncture method was used in 53% of the patients; the fistula needles were inserted in the antegrade direction in 43.9% of the patients; the arterial needle was rotated after fistula needle placement in 63.4% of the patients; and the arterial and venous needles were on the same vascular line in 15.2% of the patients. Placement of the fistula needle in the antegrade direction increased the Kt/V value 0.164 times (95% confidence interval: 0.002–0.212, p = .047).Conclusion: Antegrade placement could be a factor influencing dialysis adequacy. We suggest antegrade interventions to the fistula to maximize the patient benefit from the haemodialysis treatment.
- 19 December 2020
- Published by Frontiers Media SA in Transplant International
- Vol. 34 (3) , 445-454
Hand‐assisted retroperitoneoscopic donor nephrectomy offers more liberal use of right kidneys: lessons learned from 565 cases – a retrospective single‐center study
The introduction of laparoscopic donor nephrectomy caused a shift toward‚ left donor nephrectomy. Some centers report a significantly low rate of endoscopic right donor nephrectomy. Hand assisted retroperitoneoscopic donor nephrectomy (HARP‐DN) was introduced as a novel surgical technique, which aims to avoid intraabdominal complications. It was also reported to provide technical advantages for right‐sided DN. In this retrospective single‐center study, we evaluated the impact of HARP‐DN technique on utilization of right‐sided DNs. After the implementation of HARP‐DN on February 2009, a total of 565 DNs were performed until December 2015. The introduction of HARP‐DN technique resulted in an immediate increase in the utilization of right kidneys from 6.1% to an average of 19.6% annually. The donors ‘outcome was similar to the left‐sided and right‐sided DN groups, excluding the increased incidence of incisional hernias in left kidney donors. None of the donors developed intraabdominal complications. In conclusion, the implementation of HARP technique significantly increased the use of right sided DNs, which enables a more liberal use of donors in LDKT.
- 19 December 2020
- Published by Frontiers Media SA in Transplant International
- Vol. 34 (3) , 445-454
Hand‐assisted retroperitoneoscopic donor nephrectomy offers more liberal use of right kidneys: lessons learned from 565 cases – a retrospective single‐center study
The introduction of laparoscopic donor nephrectomy caused a shift toward‚ left donor nephrectomy. Some centers report a significantly low rate of endoscopic right donor nephrectomy. Hand assisted retroperitoneoscopic donor nephrectomy (HARP‐DN) was introduced as a novel surgical technique, which aims to avoid intraabdominal complications. It was also reported to provide technical advantages for right‐sided DN. In this retrospective single‐center study, we evaluated the impact of HARP‐DN technique on utilization of right‐sided DNs. After the implementation of HARP‐DN on February 2009, a total of 565 DNs were performed until December 2015. The introduction of HARP‐DN technique resulted in an immediate increase in the utilization of right kidneys from 6.1% to an average of 19.6% annually. The donors ‘outcome was similar to the left‐sided and right‐sided DN groups, excluding the increased incidence of incisional hernias in left kidney donors. None of the donors developed intraabdominal complications. In conclusion, the implementation of HARP technique significantly increased the use of right sided DNs, which enables a more liberal use of donors in LDKT.
- Open Access
- 13 July 2020
- Published by Wiley in Transplant Infectious Disease
- Vol. 22 (5) , e13371
COVID‐19 in kidney transplant recipients: A multicenter experience in Istanbul
Introduction: Management of COVID‐19 in kidney transplant recipients should include treatment of the infection, regulation of immunosuppression, and supportive therapy. However, there is no consensus on this issue yet. This study aimed to our experiences with kidney transplant recipients diagnosed with COVID‐19.Material and Methods: Kidney transplant recipients diagnosed with COVID‐19 from five major transplant centers in Istanbul, Turkey, were included in this retrospective cohort study. Patients were classified as having moderate or severe pneumonia for the analysis. The primary endpoint was all‐cause mortality. The secondary endpoints were acute kidney injury, the average length of hospital stay, admission to intensive care, and mechanical ventilation.Results: Forty patients were reviewed retrospectively over a follow‐up period of 32 days after being diagnosed with COVID‐19. Cough, fever, and dyspnea were the most frequent symptoms in all patients. The frequency of previous induction and rejection therapy was significantly higher in the group with severe pneumonia compared to the moderate pneumonia group. None of the patients using cyclosporine A developed severe pneumonia. Five patients died during follow‐up in the intensive care unit. None of the patients developed graft loss during follow‐up.Discussion: COVID‐19 has been seen to more commonly cause moderate or severe pneumonia in kidney transplant recipients. Immunosuppression should be carefully reduced in these patients. Induction therapy with lymphocyte‐depleting agents should be carefully avoided in kidney transplant recipients during the pandemic period.
- 13 July 2020
- Published by Wiley in Transplant Infectious Disease
- Vol. 22 (5) , e13371
Open AccessCOVID‐19 in kidney transplant recipients: A multicenter experience in Istanbul
Introduction: Management of COVID‐19 in kidney transplant recipients should include treatment of the infection, regulation of immunosuppression, and supportive therapy. However, there is no consensus on this issue yet. This study aimed to our experiences with kidney transplant recipients diagnosed with COVID‐19.Material and Methods: Kidney transplant recipients diagnosed with COVID‐19 from five major transplant centers in Istanbul, Turkey, were included in this retrospective cohort study. Patients were classified as having moderate or severe pneumonia for the analysis. The primary endpoint was all‐cause mortality. The secondary endpoints were acute kidney injury, the average length of hospital stay, admission to intensive care, and mechanical ventilation.Results: Forty patients were reviewed retrospectively over a follow‐up period of 32 days after being diagnosed with COVID‐19. Cough, fever, and dyspnea were the most frequent symptoms in all patients. The frequency of previous induction and rejection therapy was significantly higher in the group with severe pneumonia compared to the moderate pneumonia group. None of the patients using cyclosporine A developed severe pneumonia. Five patients died during follow‐up in the intensive care unit. None of the patients developed graft loss during follow‐up.Discussion: COVID‐19 has been seen to more commonly cause moderate or severe pneumonia in kidney transplant recipients. Immunosuppression should be carefully reduced in these patients. Induction therapy with lymphocyte‐depleting agents should be carefully avoided in kidney transplant recipients during the pandemic period.